Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03198026
Recruitment Status : Recruiting
First Posted : June 23, 2017
Last Update Posted : March 4, 2019
Sponsor:
Collaborators:
Genentech, Inc.
Pharmacyclics LLC.
Information provided by (Responsible Party):
Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University )

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : January 2022